Non-small cell lung cancer market projected to be worth $14.6 billion by 2024

15-Nov-2018

Following the recent spate of approvals in both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), the treatment landscape is becoming increasingly difficult to navigate for both physicians and patients, highlighting the need for better education, access, and infrastructure to support physicians’ and patients’ choices of the optimal therapies, says GlobalData

Non-small cell lung cancer market projected to be worth .6 billion by 2024

GlobalData expects the global NSCLC market to be worth $14.6 billion by 2024, greater than six-fold more than the SCLC market, which is expected to reach only $2.3 billion in the same timeframe.

Francesca Blum, MSci, UK Oncology Director at GlobalData, comments: “As SCLC and NSCLC both have more than 20 immunotherapy products currently in Phase II or III development, treatment paradigms for both forms of the disease will become increasingly complex, requiring treatments to be chosen from a growing selection of similar options.”

The FDA has already approved several drugs for lung cancer during H2 2018, including targeted tyrosine kinase inhibitors and immunotherapies.

Pfizer has had a particularly good streak, with approvals for Vizimpro (dacomitinib) in September for untreated patients with epidermal growth factor receptor (EGFR)-mutated NSCLC and Lorbrena (lorlatinib) in early November for previously treated patients with anaplastic lymphoma kinase (ALK)-mutated NSCLC.

Blum continues: “These approvals will boost Pfizer’s lung cancer revenues, which have suffered recently as its original ALK inhibitor Xalkori (crizotinib) has faced sales pressure from Takeda’s and Novartis’ newer ALK-targeted competitors, Alunbrig (brigatinib) and Zykadia (ceritinib), respectively.”

Alongside the much-needed increase of targeted treatment options for NSCLC patients with ALK or EGFR mutations, the use of immuno-oncology is also expanding, particularly into subtypes of lung cancer with significant unmet needs.

In August, Bristol-Myers Squibb’s Opdivo (nivolumab) was granted accelerated approval by the FDA for metastatic SCLC, making it the first immunotherapy for this type of lung cancer.

A key aim of this year’s Lung Cancer Awareness Month campaign is to ensure public awareness about screening programs and resources to help with the early detection of lung cancer.

Sign up for your free email newsletter

Blum adds: “Improvements in diagnosis will no doubt contribute to increasing global incidence rates, which we currently expect to rise in SCLC and NSCLC at annual growth rates of 2.05% and 3.24%, respectively, giving players further opportunities to gain from this buoyant market.”

Companies

Featured Companies

Related Content

Eli Lilly’s acquisition of Loxo Oncology will result in quick return of investment
Eli Lilly’s acquisition of Loxo Oncology will result in quick return of investment
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
Drug pricing and reimbursement concerns will remain the leading impediment to industry growth in 2019
Drug pricing and reimbursement concerns will remain the leading impediment to industry growth in 2019
R&D returns fall to lowest level in 9 years, says Deloitte and GlobalData
R&D returns fall to lowest level in 9 years, says Deloitte and GlobalData
Drug development in neuroimmunology to witness strong growth in the 8MM
Drug development in neuroimmunology to witness strong growth in the 8MM
Immuno-oncology drug development and personalised medicine will continue to reshape the pharma industry in 2019
Immuno-oncology drug development and personalised medicine will continue to reshape the pharma industry in 2019
GSK and Pfizer deal shows shift in strategy shift to create the leader in over-the-counter products
GSK and Pfizer deal shows shift in strategy shift to create the leader in over-the-counter products
Big Data and AI to transform healthcare by driving innovation, growing revenues and increasing operational efficiencies
Big Data and AI to transform healthcare by driving innovation, growing revenues and increasing operational efficiencies
Bayer receives European approval for haemophilia drug Jivi ... but has stiff competition ahead
Bayer receives European approval for haemophilia drug Jivi ... but has stiff competition ahead
Second failure of AstraZeneca’s Imfinzi + tremelimumab combination significant setback says GlobalData
Second failure of AstraZeneca’s Imfinzi + tremelimumab combination significant setback says GlobalData
Commercial opportunities for emerging infectious diseases vaccine developers
Commercial opportunities for emerging infectious diseases vaccine developers
Global atopic dermatitis market set to reach $18.3 billion by 2027
Global atopic dermatitis market set to reach $18.3 billion by 2027
Pfizer’s palbociclib is the top breast cancer drug used in clinical trials initiated in 2018
Pfizer’s palbociclib is the top breast cancer drug used in clinical trials initiated in 2018
Commercial prospects for immuno-oncology development across oncology indications in untapped cancer types or in combinations
Commercial prospects for immuno-oncology development across oncology indications in untapped cancer types or in combinations
Significant advances in diabetes medicine have been made, but many unmet needs remain
Significant advances in diabetes medicine have been made, but many unmet needs remain